First issued patent of a portfolio of applications covering the new minimally-invasive procedure to treat snoring
IRVINE, CA, June 21, 2018 (GLOBE NEWSWIRE) — Zelegent, Inc., a medical technology company developing innovative tools for otolaryngologist sleep specialists, announced that its Elevoplasty™ procedure has received issued U.S. patent number 9,943,305, entitled “Surgical Procedure and Related Apparatus for Treating Sleep Apnea by Lifting, Suspending, and Stiffening the Soft Palate.”
“This patent secures Zelegent’s position in the development of advanced, minimally invasive devices for the sleep specialist otolaryngology community to offer patients a novel, minimally-invasive, office based procedure that requires no general anesthesia, and that may alleviate snoring by shortening, suspending, and stiffening a patient’s soft palate,” said Alexander K. Arrow, MD, Chief Executive Officer of Zelegent, Inc.
A Premarket Notification for the Zelegent, Inc. Elevo™ Kit, which was evaluated in the multi-center S.I.LE.N.C.E. Study, is under review by the Food and Drug Administration.
The complete data set from the fifty-two (52) patient, 8-center Snoring Intervention via Elevoplasty™ in a Non-surgical Clinical Environment (S.I.LE.N.C.E.) trial will be presented in October at the 2018 meeting of the American Association of Otolaryngology in Atlanta, GA by Dr. M. Boyd Gillespie, Chairman of the Department of Otolaryngology at the University of Tennessee Health Science Center and West Cancer Center.
About Zelegent, Inc.
Zelegent, Inc. (formerly Snorx, Inc.), is a medical technology company developing innovative tools for physicians who treat sleep disorders. The company’s mission is to develop and provide minimally-invasive devices to treat snoring. Elevoplasty™, is a patented, office-based procedure. The Elevo™ Kit is an investigational device only and is not for sale in the United States.
For updates, find Zelegent online at www.zelegent.com, or
ZelegentTM and Silence is HealthyTM are trademarks of Zelegent, Inc. Zelegent is part of the EvoNexus family of companies.
For further information, please contact:
Alexander K. Arrow, MD, CFA
Chief Executive Officer
5151 California Ave., Suite 150
Irvine, CA 92617